Establishment Labs Reports Q3 Results, Raises 2026 Revenue Guidance

Revenue rose 33.9% year over year to $72.0 million. GAAP net loss was $10.7 million, or $(0.35) per share; adjusted EBITDA was $6.4 million. The company raised full-year revenue guidance to $269 million-$271 million and reported FDA approval for additional smaller Motiva implant sizes.